Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Role of the forkhead protein FoxO1 in β cell compensation to insulin resistance
Haruka Okamoto, … , ndrew Ward,, Domenico Accili
Haruka Okamoto, … , ndrew Ward,, Domenico Accili
Published March 1, 2006
Citation Information: J Clin Invest. 2006;116(3):775-782. https://doi.org/10.1172/JCI24967.
View: Text | PDF
Research Article Endocrinology Article has an altmetric score of 6

Role of the forkhead protein FoxO1 in β cell compensation to insulin resistance

  • Text
  • PDF
Abstract

Diabetes is associated with defective β cell function and altered β cell mass. The mechanisms regulating β cell mass and its adaptation to insulin resistance are unknown. It is unclear whether compensatory β cell hyperplasia is achieved via proliferation of existing β cells or neogenesis from progenitor cells embedded in duct epithelia. We have used transgenic mice expressing a mutant form of the forkhead-O1 transcription factor (FoxO1) in both pancreatic ductal and endocrine β cells to assess the contribution of these 2 compartments to islet expansion. We show that the mutant FoxO1 transgene prevents β cell replication in 2 models of β cell hyperplasia, 1 due to peripheral insulin resistance (Insulin receptor transgenic knockouts) and 1 due to ectopic local expression of IGF2 (Elastase-IGF2 transgenics), without affecting insulin secretion. In contrast, we failed to detect a specific effect of the FoxO1 transgene on the number of periductal β cells. We propose that β cell compensation to insulin resistance is a proliferative response of existing β cells to growth factor signaling and requires FoxO1 nuclear exclusion.

Authors

Haruka Okamoto, Marta Letizia Hribal, Hua V. Lin, William R. Bennett, ndrew Ward,, Domenico Accili

×

Figure 1

Detection of c-Myc–FoxO1 fusion proteins.

Options: View larger image (or click on image) Download as PowerPoint
Detection of c-Myc–FoxO1 fusion proteins.
(A) Insr Western blot. We dete...
(A) Insr Western blot. We detected Insr by Western blotting of liver, brain, and muscle extracts of WT mice. L1 mice express Insr in liver and brain, but not muscle. Insr–/– mice do not express Insr in liver while L2 mice are Insr transgenic knockouts with Insr expression limited to liver and β cells (26). (B) FoxO1 Western blot. We performed immunoprecipitations with anti–c-Myc antiserum and Western blotting with anti-FoxO1 antiserum (upper panel). As a control, we show immunoblotting with anti-FoxO1 (middle panel) and antitubulin antisera (lower panel). (C) Pancreatic immunohistochemistry. We performed immunostaining of pancreatic sections from WT, 307, and 305 mice with anti–c-Myc antiserum to detect transgene-encoded FoxO1 (left panels, red). DNA counterstaining with DAPI is shown in right panels. We show representative sections to illustrate the difference between transgene-positive and transgene-negative cells, indicated by the yellow arrows. Magnification, ×40 (top 3 rows); ×100 (bottom row).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 7 patents
74 readers on Mendeley
1 readers on CiteULike
See more details